Compare Merck & Co., Inc. (MRK) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance

Merck & Co., Inc.Trade

State Street SPDR S&P Homebuilders ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while State Street SPDR S&P Homebuilders ETF trades at $105.91. The key difference: Merck & Co., Inc. pays a 2.73% dividend while State Street SPDR S&P Homebuilders ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.

	MRK	XHB
Market Cap	$307.25B	—
Sector	Health	Broad Market / Factor
52-Week High	$129.52	$121.36
52-Week Low	$77.60	$94.86
Enterprise Value	$350.66B	—
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

State Street SPDR S&P Homebuilders ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

XHB

BlackRock Canada announces July 2026 monthly cash distributions for iShares ETFs.Blackrock Asset Management Canada Limited · 13 hours agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About State Street SPDR S&P Homebuilders ETF

XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.